Surveillance-based study | cycEVA study | ||||
---|---|---|---|---|---|
Included population | N | PIVE % (95%CIb) | N | PIVE % (95%CIb) | |
Crude | All patients | 1326 | 35 (-38; 73) | 436 | 58 (-81; 95) |
▪ Delay onset-swabbing less than four days | 1175 | 35 (-45; 74) | 381 | 57(-87; 95) | |
EU case definition | 701 | 14 (-131; 72) | 377 | 53 (-109; 95) | |
▪ Delay onset-swabbing less than four days | 627 | 5 (-161; 70) | 336 | 64 (-104; 95) | |
Adjusted models | All patients | ||||
▪ full modelc | 301 | 75 (-293; 98) | |||
▪ SISSS covariatesd | 993 | 62 (-5; 87) | 351 | 65 (-221; 96) | |
All patients and delay onset-swabbing less than four days | |||||
▪ full modelc | 258 | 77 (-296; 98) | |||
▪ SISSS covariatesd | 853 | 58 (-21; 85) | 302 | 67 (-211; 97) | |
EU case definition | |||||
▪ full modelc | 255 | 71 (-402; 98) | |||
▪ SISSS covariatesd | 644 | 41 (-95; 82) | 299 | 59 (-300; 96) | |
EU case definition and delay onset-swabbing less than four days | |||||
▪ full modelc | 231 | 72 (-290; 99) | |||
▪ SISSS covariatesd | 568 | 48 (-110; 82) | 263 | 68 (-215; 97) |